||5R01CA242742-02 Interpret this number
||H. Lee Moffitt Cancer Ctr & Res Inst
||Identifying and Reducing Disparities in Patient-Reported Outcomes Among African American Prostate Cancer Survivors
We propose a project to reduce morbidity as related to health disparities in prostate cancer survivors by
identifying disparities in symptom burden and their contributors among African American prostate cancer
survivors. The limited research reported that patient-reported quality of life outcomes are worse in African
American compared to White prostate cancer survivors. Most importantly, other critically important symptom
burden outcomes are largely understudied and overlooked in minorities. Previous research suggests African
American prostate cancer survivors likely experience signiﬁcant symptom burden for outcomes that are
avoidable or treatable. The proposed project will address these critical public health concerns in the growing
population of African American prostate cancer survivors.!
This project aims to 1) Compare symptom burden between African American and White prostate cancer
survivors, 2) Identify multilevel modiﬁable risk factors for worse symptom burden among both African
American and White prostate cancer survivors, such as cultural, health behavior-related, psychosocial, and
racial discrimination factors, and 3) Identify multilevel non-modiﬁable risk factors for worse symptom burden,
such as genetic, clinical, treatment-related, and demographic factors. The risk factors we will study are
informed by an adapted multilevel contextual model examining the levels of the person, social environment,
and healthcare system.!
This will be among the ﬁrst and most comprehensive studies we are aware of to compare symptom burden
between African American and White prostate cancer survivors. It will be the ﬁrst we are aware of to identify
modiﬁable and non-modiﬁable risk factors for worse symptom burden. These risk factor data will allow us to
develop targeted interventions and identify high-risk individuals for monitoring and early intervention. In
summary, this project's focus on identifying disparities and their risk factors supports the Healthy People 2020
goals of eliminating health disparities and improving quality of life in cancer survivors.
Meta-Analysis of Quality of Life in Cancer Patients Treated with Immune Checkpoint Inhibitors.
, Eisel S.L.
, Bowles K.E.
, Hoogland A.I.
, James B.W.
, Small B.J.
, Sharpe S.
, Hyland K.A.
, Bulls H.W.
, Christy S.M.
, et al.
Journal of the National Cancer Institute, 2021-09-11; , .